Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.50 |
| ▸ | KAT7 | O95251 | 1/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799838 | 0.87 | LIMK2 (0.55) | STSKDM4EPKM | |
| SCHEMBL6709313 | 0.86 | ACKR3 (0.45) | ACKR3KAT7KAT8SCN9AHTR6 | |
| SCHEMBL6711024 | 0.86 | HTR6 (0.46) | ACKR3KAT7KAT8SCN9AHTR6 | |
| SCHEMBL6286686 | 0.85 | FEN1 (0.47) | ACKR3KAT7KAT8SCN9AHTR6 | |
| SCHEMBL6714853 | 0.83 | PTGES (0.46) | ACKR3KAT7KAT8HTR6BCHE | |
| SCHEMBL6286641 | 0.81 | MAPT (0.46) | ACKR3HTR6BCHE | |
| SCHEMBL5870694 | 0.81 | PTPRB (0.52) | ACKR3KAT7KAT8HTR6BCHE | |
| SCHEMBL5870788 | 0.81 | ACKR3 (0.50) | ACKR3KAT7KAT8HTR6BCHE | |
| SCHEMBL5870776 | 0.81 | ACKR3 (0.50) | ACKR3KAT7KAT8HTR6BCHE | |
| SCHEMBL5871030 | 0.81 | ACKR3 (0.50) | ACKR3KAT7KAT8HTR6BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872716-B2 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | WU XINHE (US) | 2004-11-25 | — | — | US | disclosed |
| US-6703383-B2 | HETEROCYCLIC COMPOUNDS COMPRISING A SULFONAMIDE GROUP TO TREAT DISEASES SUCH AS PSYCHOLOGICAL DISORDERS CAUSED BY ONE OR MORE PROTEIN-G COUPLED RECEPTORS OR LIGAND -GATED ION CHANNELS | SEPRACOR, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | SEPRACOR INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002022579-A2 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065265-A1 | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | TRPV1, CNR2, TRPM5 | ACKR3 1123/4885KAT7 3305/4885KAT8 2785/4885 |
| US-20040235832-A1 | ANTIPSYCHOTIC SULFONAMIDE-HETEROCYCLES, AND METHODS OF USE THEREOF | TRPV1, CNR2, TRPM5 | ACKR3 1123/4885KAT7 3305/4885KAT8 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.